CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...

Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in RTX-240 Phase 1 ...

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for ...

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational ...

Rubius Therapeutics has pulled the plug on its lead drug after its first use in a phase 1b generated “uninterpretable” data. The data capped off a series of setbacks for the phenylketonuria (PKU) ...

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...

Healthcare & Pharmaceuticalscategory Kennedy plans studies to look for environmental contributors to autism 4:48 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Baby food makers are failing ...

Rubius Therapeutics’ plan to revive its red blood cell therapy research with a new approach has run out of time and money, and the biotech is now looking to strike a deal to salvage what’s left of the ...

ElXokas dice que TWITCH no lo ha "tratado bien", y que el 2020 fue su ultima reunión con la plataforma para firmar contrato como lo tienen con Ibai, Grefg, Rubius y Auron La llegada de una nueva ...

The Swiss government is open to revising its offer to the United States in response to planned heavy tariffs, Business Minister Guy Parmelin said, as experts warned the 39% import duties announced by ...